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Conclusion Based on these results, we conclude that 
SHLA and Lan-2 are promising leptin receptor inhibitors 
which could be used to block leptin activity, eliminating 
its negative effects on activities related to carcinogenesis. 
However, the selection of a specific antagonist should be 
related to tumour type.
Keywords Ovarian cell lines · ObR antagonists · Cell 
cycle · Signalling pathways
Introduction
Leptin is a small (16-kDa) protein produced and secreted 
by adipose tissue, which is involved in appetite regula-
tion, bone formation and reproductive function. Recent 
studies indicate that leptin via stimulatory action on cell 
proliferation, apoptosis and angiogenesis can promote an 
aggressive cancer [1–3]. Epidemiological studies have 
suggested a positive correlation between obesity and an 
increased risk of different cancers [4]. Serum leptin lev-
els have been reported to be higher in overweight and 
obese women than in normal-weight women [5]. The 
normal level of leptin is about 4 ng/mL, in obese peo-
ple a tenfold higher concentration has been noted, and 
in extremely obese patients it can range up to 100 ng/
mL [6]. Cancer risk is higher among overweight (about 
16 %) and obese (about 30 %) people [7]. Uddin et al. [8] 
revealed a significant association between leptin receptor 
(ObR) overexpression and poor survival rates in 59.2 % 
of epithelial ovarian cancers. Leptin and its receptors are 
overexpressed in different human cancers [9]. It has been 
proposed as a marker of prostate, breast and oesophageal 
cancer [10, 11] and one of the six markers of ovarian 
cancer [12].
Abstract 
Introduction A number of leptin receptor antagonists have 
been synthesised for therapeutic use, with pre-clinical tests 
suggesting their future use in anticancer therapy. To our 
knowledge, there are no data concerning the possible appli-
cation of leptin receptor blockers in ovarian cancer.
Methods In this study, we evaluated two leptin receptor 
antagonists: superactive human leptin antagonist (SHLA) 
and quadruple leptin mutein, Lan-2 (L39A/D40A/F41A/
I42A), on cell proliferation (Alamar Blue test, BrdU 
assay), cell cycle gene (qPCR) and protein expression 
(Western blot) and cell signalling pathways (Western blot) 
in three different types of cell lines: OVCAR-3, CaOV-3 
and HOSEpiC.
Results Both receptor blockers had no effect on non-can-
cerous HOSEpiC cell line proliferation; however, both 
reversed the stimulatory effect of leptin on CaOV-3 cell line 
proliferation to control levels and to below control levels 
in OVCAR-3 cells. In metastatic carcinoma CaOV-3, both 
ObR antagonists had an inhibitory effect on the cdk2/cyclin 
D1 complex, while in serous carcinoma, OVCAR-3, they 
only had an effect on cdk2 and cdk4 protein expression. 
SHLA had an inhibitory effect on all investigated signal-
ling pathways in OVCAR-3, while only on Stat3 in CaOV-
3. Lan-2 had an inhibitory effect on Stat3 and ERK1/2 in 
CaOV-3, while in OVCAR-3 it only affected Akt protein 
phosphorylation.
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Ptak et al. [2], using an OVCAR-3 cell line, showed 
that leptin promotes cell line growth by upregulating 
genes and proteins responsible for inducing cell prolif-
eration, as well as downregulating proapoptotic genes 
and proteins in apoptotic pathways. Chen et al. [13] 
demonstrated that leptin upregulates the expression of 
cyclin D1 and Mcl-1, stimulating cell growth by acti-
vating the PI3 K/Akt and MEK/ERK1/2 pathways in 
the OVCAR-3 cell line. Cuello-Fredes et al. [3] showed 
serum and ascites leptin levels were significantly higher 
in overweight patients with worse survival. Moreover, 
they found worse overall survival in patients expressing 
higher leptin/ObRb mRNA levels.
Currently several groups of scientists are working on 
the synthesis of molecules that block the leptin receptor 
(ObR). A number of leptin receptor antagonists have been 
synthesised for therapeutic use, with several complet-
ing pre-clinical testing [14], suggesting their future use 
in anticancer therapy. The leptin antagonists Aca-1 and 
Allo-aca inhibit leptin-stimulated proliferation in breast 
cancer cells, MCF-7 and MDA-MB-23 [15]. Another lep-
tin antagonist LDFI (leptin binding site I) also inhibits lep-
tin-stimulated proliferation of breast cancer cells, MCF-7 
and SKBR-3 [16]. Lan-1 has been shown to inhibit lep-
tin signalling in the prostate cancer cell line LNCaP [17]. 
Bain et al. [18] have shown that superactive human leptin 
antagonist (SHLA) alone or in combination with cisplatin 
is a potential anticancer agent in gastro-oesophageal adeno-
carcinomas. Our previous work has shown that SHLA can 
reverse leptin-induced hormone secretion in porcine ovar-
ian follicles [19]. To our knowledge, there are currently no 
data concerning the possible application of leptin receptor 
blockers in epithelial ovarian cancer.
Epithelial ovarian cancers are classified based on their 
cell type, serous (30–70 %), endometrioid (10–20 %), 
mucinous (5–20 %), clear cell (3–10 %) or undifferenti-
ated (1 %). Therefore, we used four ovarian cancer cell 
lines isolated from different histological carcinomas: 
OVCAR-3 serous carcinoma, SKOV-3 TNF-resistant 
carcinoma, CaOV-3 metastatic carcinoma and TOV-21G 
clear-cell carcinoma. The cell lines were exposed to two 
leptin antagonists: superactive human leptin antagonist 
(SHLA) and quadruple leptin mutein Lan-2 (L39A/D40A/
F41A/I42A), which bind to leptin receptors but do not 
activate them.
We tested the antagonists action on the expression 
of the cell cycle, apoptosis-related genes, proteins and 
the standard pathways of action of anticancer cell lines, 
with the highest receptor expression compared to action 




Ovarian Epithelial Cell Medium (OEpiCM) was obtained 
from Scintila (Jihlava, Czech Republic). McCoy’s 5a 
Medium Modified, Dulbecco’s Modified Eagle’s Medium 
(DMEM), RPMI-1640, MCDB 105 Medium and Medium 
199, foetal bovine serum (FBS, heat inactivated), penicillin 
and streptomycin were obtained from the Sigma Chemical 
Co. (St. Louis, MO, USA). Leptin was obtained from the 
Sigma Chemical Co. (St. Louis, MO, USA). Leptin recep-
tor antagonists were obtained from Protein Laboratories 
Rehovot (PLR) Ltd. (Rehovot, Israel).
Cell culture
Human Ovarian Surface Epithelial Cells (HOSEpiC), (Scin-
tila, Jihlava, Czech Republic) were cultured in OEpiCM. 
Human ovarian epithelial carcinoma cell lines, OVCAR-3, 
CaOV-3, SK-OV-3 and TOV-21G, were obtained from the 
American Type Culture Collection (Manassas, VA, USA). 
Cells were routinely cultured in RPMI-1640 supplemented 
with 20 % FBS, DMEM with 10 % FBS, McCoy’s 5a 
medium supplemented with 10 % FBS and in a 1:1 mixture 
of medium 199 and MCBD 105 medium with 15 % FBS, 
respectively. All media were supplemented with 50 IU/mL 
of penicillin and 50 μg of streptomycin. Cells were grown 
in 75 cm2 tissue culture dishes (Nunc, Denmark) in a 37 °C 
incubator with a humidified mixture of 5 % CO2:95 % air.
qPCR analysis
Assuming the expression of the gene for the leptin recep-
tor in cancerous and non-cancerous human ovarian epi-
thelial cell line and action of leptin on ObR gene expres-
sion, cells were seeded into 96-well culture plates at a 
density of 1 × 104 cells/well HOSEpiC, 1 × 104 cells/well 
SK-OV-3, 1.5 × 104 cells/well TOV-21G, 1.5 × 104 cells/
well CaOV-3 and 1 × 104 cells/well OVCAR-3. The next 
day the medium was changed and the cells were treated 
with leptin at two doses, 40 ng/mL and 100 ng/mL, for 
24 h. Total RNA isolation and cDNA synthesis were per-
formed using the TaqMan Gene Expression Cell-to-CT Kit 
(Applied Biosystems, Carlsbad, CA, USA) following the 
manufacturer’s protocol. Amplifications were performed 
using the StepOnePlus system (Applied Biosystems, Carls-
bad, CA, USA) and the TaqMan Leptin Receptor starter 
(Cat. No. Hs00174497_m1) in combination with the 
TaqMan Gene Expression Master Mix (Applied Biosys-
tems, Carlsbad, CA, USA), following the manufacturer’s 
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instructions. A PCR was performed using a final volume of 
20 μL, including 50 ng/reaction cDNA.
In experiments with antagonists, cells were seeded into 
96-well culture plates at a density of 1.5 × 104 cells/well 
CaOV-3 and 1 × 104 cells/well OVCAR-3. The next day 
the medium was changed and the cells were treated with 
leptin at a dose of 40 ng/mL alone or with SHLA or Lan2 
at a dose of 1000 ng/mL for 24 h. cDNA synthesis was per-
formed using the TaqMan Gene Expression Cell-to-CT Kit 
(Applied Biosystems, Carlsbad, CA, USA) following the 
manufacturer’s protocol. Amplifications were performed 
using the StepOnePlus system (Applied Biosystems, Carls-
bad, CA, USA) and the TaqMan Array, Human Cyclins and 
Cell Cycle Regulation, Fast 96-well (Cat. No. 4418768) 
in combination with the TaqMan Gene Expression Master 
Mix (Applied Biosystems, Carlsbad, CA, USA), following 
the manufacturer’s instructions. A PCR was performed with 
a final volume of 10 μL including 50 ng/reaction cDNA.
The PCR conditions were as follows: pre-incubation 
for 2 min at 50 °C and 10 min at 95 °C, amplification for 
40 cycles (15 s at 95 °C and 1 min at 60 °C). The rela-
tive expression of genes was normalised against the endog-
enous reference gene GAPDH (Human GAPD Endogenous 
Control, number 4333764F) (ΔCq) and converted to rela-
tive expression (RQ) using the 2−ΔΔCq method. The results 
are expressed in the figures as relative values (RQ).
Cell proliferation BrdU assay
DNA synthesis in proliferating cells was determined by 
measuring bromodeoxyuridine (BrdU) incorporation with 
the commercial Cell Proliferation ELISA System (Roche 
Molecular Biochemicals, Mannheim, Germany). The 
cells were seeded in 96-well culture plates at a density of 
1 × 104 cells/well HOSEpiC, 1 × 104 cells/well CaOV-3 
and 0.8 × 104 cells/well OVCAR-3. Leptin was added at 
dose of 40 ng/mL. Leptin receptor antagonists were added 
at doses of 10, 100, 1000 ng/mL, with leptin at a dose of 
40 ng/mL. Cells were cultured for 72 h with repeated expo-
sure (the culture medium was changed every day and fresh 
compounds were added). Afterwards, the medium was 
removed and the cells were incubated for 3 h with a BrdU 
labelling solution (provided by the kit) containing 10 µM 
BrdU. The assay was performed following the manufac-
turer’s instructions. Absorbance values were measured at 
450 nm using an ELISA reader (ELx808 BIO-TEK Instru-
ments, Vinooski, VT, USA). Culture medium alone was 
used as a control for non-specific binding.
Cell proliferation Alamar Blue assay
HOSEpiC cells were seeded in 96-well culture plates at 
a density of 6 × 103 cells per well, OVCAR-3 cells were 
seeded at a density of 7 × 103 cells per well, and CaOV-3 
cells were seeded at a density of 6 × 103 cells per well. Leptin 
receptor antagonists were added at doses of 10, 100, 1000 ng/
mL, with leptin at a dose of 40 ng/mL. Cells were cultured 
for 72 h with repeated exposure (the culture medium was 
changed every day and fresh compounds were added). After 
72 h, Alamar Blue stock solution was aseptically added to the 
wells in amounts equal to 10 % of the incubation volume and 
incubated for 4 h with the cells; the assay was performed fol-
lowing the manufacturer’s instructions. The resazurin reduc-
tion was measured at a 540 nm excitation wavelength and a 
590 nm emission wavelength using a FLUORO-microplate 
reader (BIO-TECH Instruments, USA).
Western blot analysis
Cells were plated into 24-well plates at a density of 
10 × 104 cells for OVCAR-3 cells, for CaOV-3 and 
8 × 104 cells HOSEpiC cells and allowed to attach over-
night. The next day the media were changed and the cells 
were treated with 40 μg/mL leptin alone or in combination 
with 1000 μg/mL SHLA or Lan-2. To examine cell cycle 
protein expression, cells were incubated for 72 h (OVCAR-
3) or 48 h (CaOV-3, HOSEpiC). After incubation, the cells 
were washed with ice-cold PBS and lysed with Laemmli 
lysis buffer (Sigma Chemical Co., St. Louis, MO, USA). 
The lysed cells were then scraped, transferred to micro-
tubes and stored at −70 °C until analysis.
Before analysis, samples were sonicated and centrifuged 
at 15,000 × g for 15 min at 4 °C. The quantity of proteins 
was determined using the Bradford method, and the clear 
supernatant was used for electrophoresis. Equal amounts of 
protein (100 µg) from each treatment group were separated 
by SDS-PAGE and transferred to PVDF membranes using 
a Bio-Rad Mini-Protean 3 apparatus (Bio-Rad Laboratories 
Inc., Hercules, CA, USA). The blots were blocked for 1 h 
in 5 % BSA with 0.1 % Tween-20 in 0.02 M TBS buffer. 
Blots were incubated overnight with primary antibodies 
specific to ObR (ab5593, abcam, Cambridge, Great Britain; 
dilution 1:2000). After incubation with the primary anti-
body, the membranes were washed three times with 0.1 % 
Tween-20 in 0.02 M TBS buffer and incubated for 1 h with 
an appropriate horseradish peroxidase-conjugated second-
ary antibody (#7074, Cell Signaling Technology Inc., Bev-
erly, MA, USA; dilution 1:2000).
β-Actin was used as an internal loading control; mem-
branes were washed for 30 min in stripping buffer (0.25 M 
glycine, 1 % SDS, pH 2) and reprobed by overnight incu-
bation with primary antibodies specific to β-actin (A5316, 
Sigma Chemical Co., St. Louis, MO, USA; dilution 
1:2000) and for 1 h with a horseradish peroxidase-conju-
gated secondary antibody (P0447 DAKO, Glostrup, Den-
mark; dilution 1:5000).
614 Cancer Chemother Pharmacol (2016) 78:611–622
1 3
Immunopositive bands were visualised using Western 
Blotting Luminol Reagent (Santa Cruz Biotechnology Inc., 
Santa Cruz, CA, USA) and ChemiDoc™ XRS+System 
(Bio-Rad Laboratories Inc., Hercules, CA, USA). The 
relative levels of protein expression were determined 
using ImageJ software (US National Institutes of Health, 
Bethesda, MD, USA). Individual protein levels were nor-
malised to β-actin controls, and the ratio of protein to 
β-actin was normalised to 1 in the untreated control group.
To study cell cycle protein level cells were plated into 
24-well plates at a density of 10 × 104 cells for OVCAR-3 
cells and 9 × 104 cells for CaOV-3 cells and allowed to 
attach overnight. The next day the media were changed 
and the cells were treated with 40 μg/mL leptin alone or in 
combination with 1000 μg/mL SHLA or Lan-2. To exam-
ine cell cycle protein expression, cells were incubated for 
72 h (OVCAR-3) or 48 h (CaOV-3). Equal amounts of pro-
tein (60 µg) from each treatment group were separated by 
SDS-PAGE and transferred to PVDF membranes. The blots 
were blocked for 1 h in 5 % BSA with 0.1 % Tween-20 
in 0.02 M TBS buffer. Blots were incubated overnight with 
primary antibodies specific to Cyclin D1 (#2978, Cell Sign-
aling Technology Inc., Beverly, MA, USA), cdk4 (#12790), 
cdk2 (#2546), cyclin A2 (#4656) at a 1:1000 dilution and 
E2F-2 (sc-251 Santa Cruz Biotechnology Inc., Santa Cruz, 
CA, USA) at a dilution of 1:200. After incubation with the 
primary antibody, the membranes were washed three times 
with 0.1 % Tween-20 in 0.02 M TBS buffer and incubated 
for 1 h with an appropriate horseradish peroxidase-conju-
gated secondary antibody (#7074, Cell Signaling Technol-
ogy Inc., Beverly, MA, USA; dilution 1:2000 and sc-2005, 
Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA, 
respectively).
GAPDH was used as an internal loading control; mem-
branes were washed for 30 min in stripping buffer (0.25 M 
glycine, 1 % SDS, pH 2) and reprobed by overnight incuba-
tion with primary antibodies specific to GAPDH (G-8795, 
Sigma Chemical Co., St. Louis, MO, USA; dilution 1:20 
000) and for 1 h with a horseradish peroxidase-conjugated 
secondary antibody (sc-2005, Santa Cruz Biotechnology 
Inc., Santa Cruz, CA, USA dilution 1:2000).
Immunopositive bands were visualised using Western 
Blotting Luminol Reagent (Santa Cruz Biotechnology Inc., 
Santa Cruz, CA, USA) and ChemiDoc™ XRS+System 
(Bio-Rad Laboratories Inc., Hercules, CA, USA). The 
relative levels of protein expression were determined 
using ImageJ software (US National Institutes of Health, 
Bethesda, MD, USA). Individual protein levels were nor-
malised to GAPDH controls and the ratio of protein to 
GAPDH was normalised to 1 in the untreated control 
group.
To study leptin receptor signalling, the cells were treated 
with 40 ng/mL of leptin in combination with SHLA or 
Lan-2 at a concentration of 1000 μg/mL for 0, 5, 15, 30 and 
60 min. Sixty micrograms of protein from each treatment 
group was separated by 10 % SDS-PAGE. Blots were incu-
bated overnight at 4 °C with antibodies specific for phos-
pho-Stat3 (Tyr705) (#9131), Stat3 (#9132), phospho-p44/42 
MAPK (#9101), p44/42 MAPK (#9102), phospho-Akt 
(Ser473) (#9271) and Akt (#9272) at a dilution of 1:1000 
(Cell Signaling Technology Inc., Beverly, MA, USA). After 
incubation with the primary antibody, the membranes were 
washed three times and incubated for 1 h with a horserad-
ish peroxidase-conjugated secondary antibody (#7074) at 
a dilution of 1:2000 (Cell Signaling Technology Inc., Bev-
erly, MA, USA). Immunopositive bands were visualised 
using Western Blotting Luminol Reagent (Santa Cruz Bio-
technology Inc., Santa Cruz, CA, USA) and ChemiDoc™ 
XRS+System (Bio-Rad Laboratories Inc., Hercules, CA, 
USA). The relative levels of protein expression were deter-
mined using ImageJ software (US National Institutes of 
Health, Bethesda, MD, USA). Individual protein levels were 
normalised to the total amounts of signalling proteins and 
the ratio of phospho-protein to total protein was normalised 
to 1 in the untreated control group (time = 0 min).
Statistical analysis
Data were expressed as mean ± SEM from the four inde-
pendent experiments performed in triplicate. Statisti-
cal analyses were performed using GraphPad Prism 5. 
Data were analysed using a one-way analysis of variance 
(ANOVA) followed by a Tukey’s honestly significant dif-
ference (HSD) multiple range test. A value of p < 0.05 was 
considered statistically significant.
Results
The expression of the leptin receptor (ObR) gene 
in different cell lines
The expression of the leptin receptor gene varies between 
different cell lines. Assuming the expression of the gene 
for the leptin receptor in non-cancerous human ovarian epi-
thelial cell line (HOSEpiC) to be 1, we noted that in the 
SK-OV-3 cell line ObR gene expression was comparable to 
that in HOSEpiC and TOV-21G. A fivefold higher expres-
sion of ObR was noted in CaOV-3 and a ninefold higher in 
the OVCAR-3 cell line (Fig. 1).
The effect of Leptin on the expression of the leptin 
receptor (ObR) gene in different cell lines
Leptin at both doses, 40 and 100 ng/mL, significantly 
increased ObR gene expression in CaOV-3, while in 
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OVCAR-3 only a dose of 40 ng/mL had an effect (Fig. 2). 
In the other investigated cell lines, no effect on ObR gene 
expression was observed. Based on these two experi-
ments, we chose CaOV-3 and OVCAR-3, characterised by 
the highest expression of mRNA for leptin receptors and 
response to leptin supplementation, for further research.
The action of leptin receptor antagonists (SHLA 
and Lan‑2) on ObR protein level
Using Western blot analysis, we observed that leptin 
increase both short and long form of leptin receptor (ObR-
b) expression only in OVCAR-3 cell line (Fig. 3). From 
ObR antagonists, Lan-2 reversed leptin action on ObR-b 
expression to control in HOSEpiC and OVCAR-3 cells, 
while SHLA in CaOV-3 cells (Fig. 3).
The action of leptin and leptin receptor antagonists 
(SHLA and Lan‑2) on cell proliferation (Alamar Blue 
assay, BrdU assay)
Leptin at dose of 40 ng/mL (noted in plasma of overweigh 
human) had a stimulatory effect on both cancer cell lines 
proliferation (Fig. 4a, b).
Measuring cell proliferation using the Alamar Blue 
test we noted no effect of both receptor blockers on non-
cancerous HOSEpiC cell line proliferation; however, both 
receptor blockers reversed the stimulatory effect of leptin 
in CaOV-3 cell line to control levels and below control lev-
els in the OVCAR-3 cell line (Fig. 4a).
Using a BrdU incorporation assay, we noted that Lan-2 
at the highest dose (1000 ng/mL) reduces proliferation to 
below the level found in the control HOSEpiC cells. In 
the CaOV-3 cell line SHLA at a dose of 1000 ng/mL and 
Lan-2 at all doses reversed the stimulatory effect of leptin, 
and in the OVCAR-3 cell line both antagonists at all doses 
decreased leptin-stimulated cell proliferation (Fig. 4b).
The effect of SHLA and Lan‑2 on selected gene 
expression involved in cell cycle regulation in CaOV‑3 
and OVCAR‑3 cells
Based on the results of the experiments concerning the 
action of leptin receptor blockers on cell proliferation, 
we chose 1000 ng/ml for the next experiments. SHLA 
in the CaOV-3 cell line downregulated all investigated 
cell cycle progression gene expression, with the highest 
effect on CCNA1 and from cell cycle inhibitors that had 
Fig. 1  Leptin receptor (ObR) gene expression in different cell lines. 
Basal mRNA for leptin receptor was evaluated by qPCR after 24 h 
of cell culture. All the result were normalised to HOSEpiC, value 
equal to 1. Values are mean ± SEM. Statistically significant differ-
ences between cell lines in graph are indicated with different letters; 
the same letters indicating no significant differences, with a < b < c
Fig. 2  Effect of leptin on the 
expression of leptin receptor 
(ObR) gene in different cell 
lines. Each point represents 
the mean ± SEM from three 
independent experiments. 
Statistically significant different 
from control are indicated with 
different letters; the same letters 
indicating no significant differ-
ences, with a < b < c
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a stimulatory action on the CDKN1B and TP53 genes. In 
the OVCAR-3 cell lines SHLA upregulated both genes 
involved in cell cycle activation, as well as CDKN2D, 
CDKN1A, CDKN1B, TP53 cell cycle inhibitors. Addi-
tionally, SHLA increased ATM and ATR gene expression, 
which belong to the PI3/PI4 kinase family and function 
as regulators of a wide variety of downstream proteins, 
including tumour suppressor proteins p53 (Fig. 5a).
Lan-2 in CaOV-3 downregulated all investigated genes 
involved in cell cycle activation and inhibition. Addition-
ally, Lan-2 downregulated RAF1 and ATM gene expres-
sion. In OVCAR-3, Lan-2 downregulated genes involved 
in cell cycle activation, with the highest effect on CDK4, 
E2F2, E2F3, CCNA1 and CDC2. There was no effect on 
cell cycle inhibitors except for CDKN2A and p53. Addi-
tionally, an inhibitory effect on RAF-1 and a stimula-
tory effect on ATM and ATR gene expression was noted 
(Fig. 5b).
The effect of SHLA and Lan‑2 on cdk4, cdk2, cyclin 
A, cyclin D and E2F1 protein expression in CaOV‑3 
and OVCAR‑3 cells
To investigate action on protein expression, we chose cdk4 
and cyclin D from phase G1 of the cell cycle in cdk2 and 
cyclin A and from phase S, and additionally E2F1, which 
is a transcription factor with a crucial role in the control of 
the cell cycle and action on tumour suppressor proteins. In 
CaOV-3, leptin stimulated the expression of all the inves-
tigated proteins except for cyclin A2. SHLA decreased 
leptin-stimulated expression of cdk4, cyclin D1, cdk2 
and E2F1 and had no effect on cyclin A2, while Lan-2 
decreased the expression of cdk4, cyclin D1 and cdk2 
(Fig. 5c) In OVCAR-3 3 leptin stimulates the expression 
of cdk4, cdk2 and E2F1. Both SHLA and Lan-2 decreased 
the leptin-stimulated protein expression of cdk4 and cdk2. 
This suggests that both antagonists act mainly on cdk/cyc-
lin complexes (Fig. 5d).
The effect of SHLA and Lan‑2 on signalling protein 
expression in CaOV‑3 and OVCAR‑3 cells
To investigate the effect of SHLA and Lan-2 on cell signal-
ling pathways activated by leptin we chose three signalling 
proteins from different pathways: STAT, ERK1/2 and Akt. 
In the CaOV-3 cell line, both SHLA and Lan-2 inhibited 
the phosphorylation of the STAT protein, and only Lan-2 
decreased the phosphorylation of the ERK1/2 protein 
(Fig. 6a). Interestingly we did not observe the phosphoryla-
tion of the Akt protein in CaOV-3 cells (data not shown). 
In the OVCAR-3 cell line, we noted that SHLA inhibited 
phosphorylation in all the investigated proteins and that 
Lan-2 decreased only Akt phosphorylation (Fig. 6b).
Discussion
Our data clearly show differences in the expression of the 
leptin receptor gene depending on histopathological types. 
Interestingly, in the SK-OV-3 cell line, which is TNF-resist-
ant adenocarcinoma, and TOV-21G, which is clear-cell ade-
nocarcinoma, ObR gene expression was comparable to that 
seen in non-cancerous HOSEpiC. A fivefold higher expres-
sion of ObR was seen in primary ovarian cancer CaOV-3 
and a ninefold higher in serous carcinoma OVCAR-3 cells 
derived from a tumour resistant to chemotherapy. Addition-
ally, we found that only in these two cell lines, CaOV-3 and 
OVCAR-3, leptin increases its own receptors gene expres-
sion. However, only in OVCAR-3 leptin increased both 
short and long form of leptin receptor (ObR-b) protein 
Fig. 3  Changes in ObR-a 
(100 kDa) and ObR-b 
(125 kDa) protein expression 
in HOSEpiC, CaOV-3 and 
OVCAR-3 cells exposed to lep-
tin at dose 40 ng/mL and SHLA 
and Lan-2 at dose 1000 ng/mL 
with leptin at dose 40 ng/mL. 
Control value = 1.0. Densitom-
etry results were normalised 
to β-actin loading controls to 
obtain a ratio bands. All values 
marked with *(p < 0.05) are 
significantly different from 
control. All values marked with 
#(p < 0.05), ##(p < 0.01) are 
significantly different from val-
ues of leptin at dose 40 ng/mL
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expression. Di Yorio et al. [20] using rat ovarian explants 
culture described that leptin produced an increase in Ob-R 
expression in concentration-dependent manner with no 
effect at doses 30 and 100 ng/mL which is in coincidence 
with our results on non-cancerous HOSEpiC cell line.
These data show differences in the expression of the lep-
tin receptor gene depending on different histopathological 
ovarian cancer types. Differences in the expression of the 
short (ObR-a) and long (ObR-b) isoform in various endo-
metrial cancer cells have been described by Gao et al. [21]. 
Using breast cancer explant collected from patients, Ishi-
kawa et al. [22] showed that among 76 cases of breast can-
cer only 13 were negative for leptin receptor expression and 
patients with ObR expression were in the higher-risk group 
for future survival. In addition, studies conducted on ovar-
ian tumour explants indicated a worse prognosis among 
patients with a higher expression of the leptin receptor [3].
Considering leptin action on cell proliferation, we noted 
dose-dependent action in CaOV-3 and OVCAR-3, as well 
as in the non-cancerous cell line HOSEpiC. These results 
were confirmed by two independent tests (Alamar Blue, 
BrdU). The effect of leptin on proliferation has been well 
investigated in various cell types. Research carried out by 
our team demonstrated that leptin can stimulate OVCAR-3 
cell growth at doses of 2, 20, 40 and 100 ng/mL after 48 
and 72 h of treatment [2]. In addition, the stimulatory 
effect of leptin at a dose of 100 ng/mL on cell proliferation 
in another ovarian cancer cell line, BG-1, was presented 
Fig. 4  Leptin and leptin recep-
tor antagonists (SHLA and Lan-
2) action on HOSEpiC, CaOV-3 
and OVCAR-3 cells prolif-
eration measured by a Alamar 
Blue and b BrdU incorporation 
assay. Cells were treated for 
48 h with leptin at dose 40 ng/
mL alone or with antagonists 
at doses 10; 100 and 1000 ng/
mL. Each point represent the 
mean ± SEM. from three 
independent experiments of four 
replicates per treatment group. 
Statistically significant different 
from control are indicated with 
different letters; the same letters 
mean no significant differences, 
with a < b < c
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Fig. 5  Changes in selected cell cycle genes expression in CaOV-3 
and OVCAR-3 cells exposed to SHLA (a) and Lan-2 (b) at dose 
1000 ng/mL with leptin at dose 40 ng/mL for 24 h. All values marked 
with *(p < 0.05) are significantly different from leptin treated (40 ng/
mL) control. Control value = 1.0. The effect of SHLA and Lan-2 
at dose 1000 ng/mL with leptin at dose 40 ng/mL on cdk2, cyc-
lin A, cdk4, cyclin D and E2F1 protein expression in CaOV-3 (c) 
and OVCAR-3 (d) cells. GAPDH was used as a loading control for 
Western blot analysis. The representative blots of three experiments 
are shown in the panels. Cdk2, cyclin A, cdk4, cyclin D and E2F1 
densitometry results were normalised to GAPDH loading controls to 
obtain a ratio bands. Values are mean ± SEM All values marked with 
*(p < 0.05), **(p < 0.01) and ***(p < 0.001) are significantly differ-
ent from untreated control values. All values marked with #(p < 0.05), 
##(p < 0.01) and ###(p < 0.001) are significantly different from val-
ues of leptin at dose 40 ng/mL
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by Choi et al. [1]. The stimulatory effect of leptin on the 
proliferation of different breast cancer cells, T47-D [11], 
MCF7 and Zr-75-1 [10, 23–25] has also been examined. 
Furthermore, it has been found that leptin acts as a prolifer-
ation-stimulating factor in prostate, oesophageal [10], liver 
[26] and colon cancer [27]. Interestingly, Somasundar et al. 
[10] have shown that leptin can inhibit the proliferation of 
pancreas cancer cells at a dose of 0.4 and 4 ng/mL.
The main aim of this study was to determine the pos-
sible use of the leptin receptor blockers superactive human 
leptin antagonist (SHLA) and quadruple leptin mutein, 
Lan-2 (L39A/D40A/F41A/I42A), as additional therapy fac-
tors for the treatment of ovarian cancer. From ObR antago-
nists Lan-2 reversed leptin action on ObR-b expression to 
control in HOSEpiC and OVCAR-3 cells, while SHLA in 
CaOV-3 cell.
No effect of either receptor blocker on non-cancerous 
HOSEpiC cell line proliferation; however, both recep-
tor blockers reversed the stimulatory effect of leptin on 
CaOV-3 cell line proliferation to control levels and to 
below control levels in the OVCAR-3 cell line. To our 
knowledge, these are the first data that have shown the 
inhibition of leptin-stimulated proliferation in ovarian can-
cer and non-cancerous cells under the treatment of leptin 
receptor antagonists. These blockers have not, until now, 
been used in investigations of ovarian cell proliferation. Of 
the two, only SHLA has been examined on OE33 (oesoph-
ageal adenocarcinoma cells) alone or in combination with 
cisplatin by Bain et al. [18] and been shown to inhibit pro-
liferation. Using the ObR antagonists Aca-1 and Allo-aca 
Otvos et al. [15, 28] demonstrated that the leptin-stimulated 
proliferation of MCF-7 and MDA-MB-231 breast cancer 
cells (receptively) can be inhibited in a dose-dependent 
manner. Beccari et al. [29] tested the ObR antagonists Allo-
aca, D-Ser, DDD and others, showing that the majority of 
tested leptin receptor antagonists reverse the leptin-stimu-
lated proliferation of human breast cancer cells (MCF-7) 
and human colon adenocarcinoma cells (HT29). Catalano 
Fig. 6  Effect of SHLA and Lan-2 at dose 1000 ng/mL on phospho- 
and total: STAT, ERK1/2 in CaOV-3 (a) and on STAT, AKT, ERK1/2 
in OVCAR-3 (b) cells. Blots are representative of three experiments. 
The results of densitometry analyses are expressed as phospho-pro-
tein band density normalised to the density of the total form (load-
ing control) bands. All values marked with *(p < 0.05), **(p < 0.01) 
and ***(p < 0.001) are significantly different from control values. All 
values marked with #(p < 0.05), ##(p < 0.01) and ###(p < 0.001) are 
significantly different from values of leptin at dose 40 ng/mL
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et al. [16] described reversed leptin-stimulated prolifera-
tion to control levels in the breast cancer cells MCF-3 and 
SKBR-3 in a dose-dependent manner using another LDFI 
ObR antagonists. In addition, Scolaro et al. [30] showed 
a dose-dependent effect of Allo-aca on the cell prolifera-
tion of RF/6A (monkey endothelial retinal cells) and BCE 
(bovine endothelial corneal cells).
Going inside the mechanism of action, we showed that in 
the CaOV-3 cell line both SHLA and Lan-2 downregulate 
all investigated cell cycle progression of gene expression 
and that cell cycle inhibitors had a stimulatory effect on 
CDKN1B and TP53 and an inhibitory effect on CDKN2C. 
From the selected protein expression, both SHLA and 
Lan-2 decreased the leptin-stimulated expression of cdk4, 
cyclin D1 and cdk2, and SHLA additionally affected E2F1 
and had no effect on cyclin A2. In OVCAR-3, only Lan-2 
downregulated genes involved in cell cycle activation and 
had an inhibitory effect on RAF-1 and a stimulatory effect 
on ATM and ATR gene expression. Both SHLA and Lan-2 
decreased leptin-stimulated protein expression by cdk4 and 
cdk2 and had no effect on cyclin D1 and A2. The impact of 
leptin on cell cycle gene and protein expression in different 
cancer cells is well established. In OVCAR-3 ovarian can-
cer cells, Chen et al. [31] have shown that leptin at a dose 
of 50 ng/mL can stimulate the expression of cyclin D1. In 
the same year, Ptak et al. [2] demonstrated similar changes 
in cyclin D1 expression in the OVCAR-3 cell line under the 
influence of 40 ng/mL of leptin and additionally on cyclin 
A expression. A stimulatory effect on cyclin D1 protein 
expression was also shown in breast cancer [31, 32], endo-
metrial cancer [33] and colon cancer cells [34] and in hepa-
tocellular carcinoma [35].
To our knowledge, there are no data concerning the 
action of ObR antagonists on cell cycle gene expression. 
Our data clearly show different effects depending on cancer 
cell types. In chemoresistant OVCAR-3 cells, SHLA had 
no inhibitory effect on cell cycle progression gene expres-
sion and decreased only cdk2 and cdk4 protein expression 
without having an effect on cyclin A2 and D1. In CaOV-3, 
both ObR blockers down regulated the cell cycle progres-
sion gene and, apart from cdk2 and cdk4, cyclinD pro-
tein expression. Interestingly, our data showed a lack of 
an effect by both ObR antagonists on E2F1 in OVCAR-3 
cells, but downregulation in CaOV-3 cells under the influ-
ence of SHLA. Reimer et al. [36] suggested that the dereg-
ulation of E2F factors is one of the most important events 
in the chemotherapy resistance formation of ovarian cancer, 
confirming that OVCAR-3 cells are chemoresistant. E2F1 
factor, which is a transcription activator promoting the cell 
cycle, is overexpressed in epithelial ovarian cancers (EOC) 
and is associated with higher stage and tumour grade [37].
In spite of the statement by Masamha et al. [38], who, 
based on an experiment on A2780 and SK-OV-3 cells, 
showed that cyclin D1 inhibition is necessary to inhibit 
cell cancer growth and is a potential therapeutic target in 
ovarian cancer cells, we declare that both ObR blockers, 
by downregulating cdk2 and cdk 4, can downregulate the 
formation of the cyclin A/cdk2 and cyclin D/cdk4 complex 
and inhibit cell proliferation. In addition, the direct impact 
on cell cycle gene expression action on cycle proliferation 
can be the result of the effect on signalling pathways.
Leptin is able to activate several signalling pathways, 
such as JAK/Stat3, MAPK/ERK and PI3 K/Akt, in vari-
ous cell types. In ovarian cancer, it has been demonstrated 
by Chen et al. [13] that leptin activates Akt and ERK1/2 
proteins in the OVCAR-3 cell line. Uddin et al. [8] showed 
that leptin stimulates the activation of the PI3 K/Akt path-
way in MDAH2774 and SK-OV-3 ovarian cancer cells. In 
our data, we have shown that leptin stimulates the phospho-
rylation of Stat3, ERK1/2 and Akt. [2]. The activation of 
the mentioned pathways by leptin has also been described 
in endometrial [21], prostate [39], liver [32] and colon can-
cer cells [40].
As a second messenger system involved in possible 
action on leptin receptor antagonists, we investigated 
the effect on the JAK/Stat3, MAPK/ERK and PI3 K/Akt 
pathways. In OVCAR-3 cells, SHLA inhibited the phos-
phorylation of all tested signalling proteins, which was 
correlated with inhibitory effect on leptin-stimulated cell 
proliferation. Lan-2 acted only on the Akt phosphoryla-
tion and, however, additionally downregulated ObR-b 
protein expression. We suggest that a stronger inhibition 
of proliferation observed under the influence of Lan-2 is 
a consequence of the downregulation ObR-b. In CaOV-
3, Lan-2 inhibited Stat3 and ERK1/2 proteins and in the 
consequence decreased leptin-stimulated cell prolifera-
tion. SHLA only inhibited Stat3 and, however, in opposite 
to OVCAR-3 additionally downregulated ObR-b protein 
expression in CaOV-3. These results agree with the limited 
available data on ObR antagonist actions on cell signalling. 
The Lan-1 antagonist, which is similar to Lan-2, effectively 
inhibited leptin-induced phosphorylation of Jak2, Akt and 
ERK1/2 in a dose-dependent manner in the LNCaP pros-
tate cancer cell line (Samuel–Mendelhson et al. 2011). In 
addition, Otvos et al. (2011) have shown that Aca1 can 
inhibit Stat3 phosphorylation in MCF-7 cells. In MCF-7 
and SKBR3 breast cancer cells, pre-treatment with a LDFI-
leptin receptor antagonist abrogated the leptin activation of 
Jak2, Stat3, Akt and ERK1/2 proteins [16].
In summary: (1) In metastatic carcinoma CaOV-3 both 
ObR antagonists had an inhibitory effect on the cdk2/cyclin 
D1 complex, while in serous carcinoma, OVCAR-3, they 
had an effect only on cdk2 and cdk4 protein expression, (2) 
SHLA had an inhibitory effect on all the investigated sig-
nalling pathways in OVCAR-3, but only on Stat3 in CaOV-
3, (3) Lan-2 had an inhibitory effect on Stat3 and ERK1/2 
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CaOV-3, while in OVCAR-3 it only had an effect on Akt 
protein phosphorylation.
In conclusion, to our knowledge this study is the first 
to show the possible use of leptin receptor antagonists 
in blocking the proliferation and progression of epithe-
lial ovarian tumours. Based on the results we suggest that 
SHLA and Lan-2 are promising leptin receptor inhibitors 
that could be used to block leptin activity, eliminating its 
negative effects on activities related to ovarian carcinogen-
esis. However, selection of an antagonist for use should be 
related to tumour type. Future studies should be carried out 
using explants from patients with ovarian cancer and then 
validated in in vivo models, which would allow the investi-
gation of the effects of leptin receptor antagonists on living 
organisms.
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